These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 19496193)

  • 1. Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.
    Peralta S; Cottone C; Doveri T; Almasio PL; Craxi A
    World J Gastroenterol; 2009 Jun; 15(21):2628-31. PubMed ID: 19496193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
    Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome.
    Scarpellini E; Giorgio V; Gabrielli M; Filoni S; Vitale G; Tortora A; Ojetti V; Gigante G; Fundarò C; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2013 May; 17(10):1314-20. PubMed ID: 23740443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of the methodological and clinical validity of the combined lactulose hydrogen breath test with scintigraphic oro-cecal transit test for diagnosing small intestinal bacterial overgrowth in IBS patients.
    Zhao J; Zheng X; Chu H; Zhao J; Cong Y; Fried M; Fox M; Dai N
    Neurogastroenterol Motil; 2014 Jun; 26(6):794-802. PubMed ID: 24641100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small intestinal bacterial overgrowth produces symptoms in irritable bowel syndrome which are improved by rifaximin. A pilot study.
    Moraru IG; Portincasa P; Moraru AG; Diculescu M; Dumitraşcu DL
    Rom J Intern Med; 2013; 51(3-4):143-7. PubMed ID: 24620626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microscopic colitis and small intestinal bacterial overgrowth--diagnosis behind the irritable bowel syndrome?
    Stoicescu A; Andrei M; Becheanu G; Stoicescu M; Nicolaie T; Diculescu M
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):766-72. PubMed ID: 23272525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breath test for differential diagnosis between small intestinal bacterial overgrowth and irritable bowel disease: an observation on non-absorbable antibiotics.
    Esposito I; de Leone A; Di Gregorio G; Giaquinto S; de Magistris L; Ferrieri A; Riegler G
    World J Gastroenterol; 2007 Dec; 13(45):6016-21. PubMed ID: 18023092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
    Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small intestinal bacterial overgrowth is associated to symptoms in irritable bowel syndrome. Evidence from a multicentre study in Romania.
    Moraru IG; Moraru AG; Andrei M; Iordache T; Drug V; Diculescu M; Portincasa P; Dumitrascu DL
    Rom J Intern Med; 2014; 52(3):143-50. PubMed ID: 25509557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled antibiotic treatment study of small intestinal bacterial overgrowth in children with chronic abdominal pain.
    Collins BS; Lin HC
    J Pediatr Gastroenterol Nutr; 2011 Apr; 52(4):382-6. PubMed ID: 21240023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
    Zhuang X; Tian Z; Luo M; Xiong L
    BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restless legs syndrome in patients with irritable bowel syndrome: response to small intestinal bacterial overgrowth therapy.
    Weinstock LB; Fern SE; Duntley SP
    Dig Dis Sci; 2008 May; 53(5):1252-6. PubMed ID: 17934858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
    Weinstock LB; Geng B; Brandes SB
    Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rifaximin: The Revolutionary Antibiotic Approach for Irritable Bowel Syndrome.
    Triantafyllou K; Sioulas AD; Giamarellos-Bourboulis EJ
    Mini Rev Med Chem; 2015; 16(3):186-92. PubMed ID: 26202193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rifaximin for small intestinal bacterial overgrowth in patients without irritable bowel syndrome.
    Boltin D; Perets TT; Shporn E; Aizic S; Levy S; Niv Y; Dickman R
    Ann Clin Microbiol Antimicrob; 2014 Oct; 13():49. PubMed ID: 25319626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.
    Bae S; Lee KJ; Kim YS; Kim KN
    J Korean Med Sci; 2015 Jun; 30(6):757-62. PubMed ID: 26028929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty?
    Aziz I; Törnblom H; Simrén M
    Curr Opin Gastroenterol; 2017 May; 33(3):196-202. PubMed ID: 28257307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.
    Cuoco L; Salvagnini M
    Minerva Gastroenterol Dietol; 2006 Mar; 52(1):89-95. PubMed ID: 16554709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
    Pimentel M
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months.
    Meyrat P; Safroneeva E; Schoepfer AM
    Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1084-93. PubMed ID: 23066911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.